Type I and type III interferons display different dependency on mitogen-activated protein kinases to mount an antiviral state in the human gut

Frontiers in Immunology

Volumn 8, Issue APR, 2017, Pages

  Pervolaraki, Kalliopi ^a,b   Stanifer, Megan L ^a   Münchau, Stephanie ^a   Renn, Lynnsey A ^c   Albrecht, Dorothee ^a   Kurzhals, Stefan ^a   Senís, Elena ^a   Grimm, Dirk ^a   Schröder Braunstein, Jutta ^a   Rabin, Ronald L ^c   Boulant, Steeve ^a,b  

^a UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

^b GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^c CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

Author keywords

Antiviral immunity; Human gut microbiota; Interferon lambda; Interferon ; Intestinal epithelial cells; Mitogen activated protein kinases; Mucosal immunity

Indexed keywords

INTERFERON; INTERFERON RECEPTOR; MITOGEN ACTIVATED PROTEIN KINASE;

ANTIVIRAL ACTIVITY; ARTICLE; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; GENE INACTIVATION; HUMAN; HUMAN CELL; IMMUNOFLUORESCENCE TEST; IMMUNOHISTOCHEMISTRY; INNATE IMMUNITY; INTESTINE; INTESTINE EPITHELIUM CELL; LUCIFERASE ASSAY; MICROARRAY ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; RNA ISOLATION; UPREGULATION; VIRUS INFECTION; WESTERN BLOTTING;

EID: 85018421178     PISSN: None     EISSN: 16643224     Source Type: Journal    
DOI: 10.3389/fimmu.2017.00459     Document Type: Article

References (55)

1. Pott J, Hornef M. Innate immune signalling at the intestinal epithelium in homeostasis and disease. EMBO Rep (2012) 13:684-98. doi:10.1038/embor.2012.96
2. Takeuchi O, Akira S. Innate immunity to virus infection. Immunol Rev (2008) 227(1):75-86. doi:10.1111/j.1600-065X.2008.00737.x
3. Trinchieri G. Type I interferon: friend or foe? J Exp Med (2010) 207:2053-63. doi:10.1084/jem.20101664
4. Rubin DC, Shaker A, Levin MS. Chronic intestinal inflammation: inflammatory bowel disease and colitis-associated colon cancer. Front Immunol (2012) 3:107. doi:10.3389/fimmu.2012.00107
5. Kotenko SV, Gallagher G, Baurin VV, Lewis-Antes A, Shen M, Shah NK, et al. IFN-lambdas mediate antiviral protection through a distinct class II cytokine receptor complex. Nat Immunol (2003) 4:69-77. doi:10.1038/ni875
6. Sheppard P, Kindsvogel W, Xu W, Henderson K, Schlutsmeyer S, Whitmore TE, et al. IL-28, IL-29 and their class II cytokine receptor IL-28R. Nat Immunol (2003) 4:63-8. doi:10.1038/ni873
7. Prokunina-Olsson L, Muchmore B, Tang W, Pfeiffer RM, Park H, Dickensheets H, et al. A variant upstream of IFNL3 (IL28B) creating a new interferon gene IFNL4 is associated with impaired clearance of hepatitis C virus. Nat Genet (2013) 45:164-71. doi:10.1038/ng.2521
8. Donnelly RP, Kotenko SV. Interferon-lambda: a new addition to an old family. J Interferon Cytokine Res (2010) 30:555-64. doi:10.1089/jir.2010.0078
9. Ivashkiv LB, Donlin LT. Regulation of type I interferon responses. Nat Rev Immunol (2014) 14:36-49. doi:10.1038/nri3581
10. Durbin RK, Kotenko SV, Durbin JE. Interferon induction and function at the mucosal surface. Immunol Rev (2013) 255:25-39. doi:10.1111/imr.12101
11. Sommereyns C, Paul S, Staeheli P, Michiels T. IFN-lambda (IFN-lambda) is expressed in a tissue-dependent fashion and primarily acts on epithelial cells in vivo. PLoS Pathog (2008) 4:e1000017. doi:10.1371/journal.ppat.1000017
12. Mordstein M, Neugebauer E, Ditt V, Jessen B, Rieger T, Falcone V, et al. Lambda interferon renders epithelial cells of the respiratory and gastrointestinal tracts resistant to viral infections. J Virol (2010) 84:5670-7. doi:10.1128/JVI.00272-10
13. Odendall C, Kagan JC. The unique regulation and functions of type III interferons in antiviral immunity. Curr Opin Virol (2015) 12:47-52. doi:10.1016/j.coviro.2015.02.003
14. Hoffmann H-H, Schneider WM, Rice CM. Interferons and viruses: an evolutionary arms race of molecular interactions. Trends Immunol (2015) 36:124-38. doi:10.1016/j.it.2015.01.004
15. Jewell NA, Cline T, Mertz SE, Smirnov SV, Flaño E, Schindler C, et al. Lambda interferon is the predominant interferon induced by influenza A virus infection in vivo. J Virol (2010) 84:11515-22. doi:10.1128/JVI.01703-09
16. Crotta S, Davidson S, Mahlakoiv T, Desmet CJ, Buckwalter MR, Albert ML, et al. Type I and type III interferons drive redundant amplification loops to induce a transcriptional signature in influenza-infected airway epithelia. PLoS Pathog (2013) 9:e1003773. doi:10.1371/journal.ppat.1003773
17. Mordstein M, Michiels T, Staeheli P. What have we learned from the IL28 receptor knockout mouse? J Interferon Cytokine Res (2010) 30:579-84. doi:10.1089/jir.2010.0061
18. Mahlakõiv T, Ritz D, Mordstein M, DeDiego ML, Enjuanes L, Müller MA, et al. Combined action of type I and type III interferon restricts initial replication of severe acute respiratory syndrome coronavirus in the lung but fails to inhibit systemic virus spread. J Gen Virol (2012) 93:2601-5. doi:10.1099/vir.0.046284-0
19. Lin JD, Feng N, Sen A, Balan M, Tseng HC, McElrath C, et al. Distinct roles of type I and type III interferons in intestinal immunity to homologous and heterologous rotavirus infections. PLoS Pathog (2016) 12:e1005600. doi:10.1371/journal.ppat.1005726
20. Pott J, Mahlakõiv T, Mordstein M, Duerr CU, Michiels T, Stockinger S, et al. IFN-lambda determines the intestinal epithelial antiviral host defense. Proc Natl Acad Sci U S A (2011) 108:7944-9. doi:10.1073/pnas.1100552108
21. Hernández PP, Mahlakõiv T, Yang I, Schwierzeck V, Nguyen N, Guendel F, et al. Interferon-γ and interleukin 22 act synergistically for the induction of interferon-stimulated genes and control of rotavirus infection. Nat Immunol (2015) 16:698-707. doi:10.1038/ni.3180
22. Mahlakoiv T, Hernandez P, Gronke K, Diefenbach A, Staeheli P. Leukocyte-derived IFN-α/β and epithelial IFN-γ constitute a compartmentalized mucosal defense system that restricts enteric virus infections. PLoS Pathog (2015) 11:e1004782. doi:10.1371/journal.ppat.1004782
23. Baldridge MT, Nice TJ, McCune BT, Yokoyama CC, Kambal A, Wheadon M, et al. Commensal microbes and interferon-γ determine persistence of enteric murine norovirus infection. Science (2015) 347:266-9. doi:10.1126/science.1258025
24. Friborg J, Ross-Macdonald P, Cao J, Willard R, Lin B, Eggers B, et al. Impairment of type I but not type III IFN signaling by hepatitis C virus infection influences antiviral responses in primary human hepatocytes. PLoS One (2015) 10:e0121734. doi:10.1371/journal.pone.0121734
25. Lazear HM, Nice TJ, Diamond MS. Interferon-γ: immune functions at barrier surfaces and beyond. Immunity (2015) 43:15-28. doi:10.1016/j.immuni.2015.07.001
26. Mordstein M, Kochs G, Dumoutier L, Renauld JC, Paludan SR, Klucher K, et al. Interferon-lambda contributes to innate immunity of mice against influenza A virus but not against hepatotropic viruses. PLoS Pathog (2008) 4:e1000151. doi:10.1371/journal.ppat.1000151
27. Clevers H. The intestinal crypt, a prototype stem cell compartment. Cell (2013) 154:274-84. doi:10.1016/j.cell.2013.07.004
28. Clevers H. Modeling development and disease with organoids. Cell (2016) 165:1586-97. doi:10.1016/j.cell.2016.05.082
29. Dixit E, Boulant S, Zhang Y, Lee AS, Odendall C, Shum B, et al. Peroxisomes are signaling platforms for antiviral innate immunity. Cell (2010) 141:668-81. doi:10.1016/j.cell.2010.04.018
30. Odendall C, Dixit E, Stavru F, Bierne H, Franz KM, Durbin AF, et al. Diverse intracellular pathogens activate type III interferon expression from peroxisomes. Nat Immunol (2014) 15:717-26. doi:10.1038/ni.2915
31. Platanias LC. Mechanisms of type-I-and type-II-interferon-mediated signalling. Nat Rev Immunol (2005) 5:375-86. doi:10.1038/nri1604
32. Goody RJ, Beckham JD, Rubtsova K, Tyler KL. JAK-STAT signaling pathways are activated in the brain following reovirus infection. J Neurovirol (2007) 13:373-83. doi:10.1080/13550280701344983
33. Zhang L, Jilg N, Shao RX, Lin W, Fusco DN, Zhao H, et al. IL28B inhibits hepatitis C virus replication through the JAK-STAT pathway. J Hepatol (2011) 55:289-98. doi:10.1016/j.jhep.2010.11.019
34. Brand S, Beigel F, Olszak T, Zitzmann K, Eichhorst ST, Otte JM, et al. IL-28A and IL-29 mediate antiproliferative and antiviral signals in intestinal epithelial cells and murine CMV infection increases colonic IL-28A expression. Am J Physiol Gastrointest Liver Physiol (2005) 289:G960-8. doi:10.1152/ajpgi.00126.2005
35. Zhou Z, Hamming OJ, Ank N, Paludan SR, Nielsen AL, Hartmann R. Type III interferon (IFN) induces a type I IFN-like response in a restricted subset of cells through signaling pathways involving both the Jak-STAT pathway and the mitogen-activated protein kinases. J Virol (2007) 81:7749-58. doi:10.1128/JVI.02438-06
36. Alase AA, El-Sherbiny YM, Vital EM, Tobin DJ, Turner NA, Wittmann M. IFNγ stimulates MxA production in human dermal fibroblasts via a MAPK-dependent STAT1-independent mechanism. J Invest Dermatol (2015) 135:1-9. doi:10.1038/jid.2015.317
37. McCracken KW, Howell JC, Wells JM, Spence JR. Generating human intestinal tissue from pluripotent stem cells in vitro. Nat Protoc (2011) 6:1920-8. doi:10.1038/nprot.2011.410
38. Bartfeld S, Bayram T, van de Wetering M, Huch M, Begthel H, Kujala P, et al. In vitro expansion of human gastric epithelial stem cells and their responses to bacterial infection. Gastroenterology (2015) 148:126-136.e6. doi:10.1053/j.gastro.2014.09.042
39. Foulke-Abel J, In J, Kovbasnjuk O, Zachos NC, Ettayebi K, Blutt SE, et al. Human enteroids as an ex-vivo model of host-pathogen interactions in the gastrointestinal tract. Exp Biol Med (Maywood) (2014) 239:1124-34. doi:10.1177/1535370214529398
40. Finkbeiner SR, Zeng XL, Utama B, Atmar RL, Shroyer NF, Estes MK. Stem cell-derived human intestinal organoids as an infection model for rotaviruses. MBio (2012) 3:e00159-12. doi:10.1128/mBio.00159-12
41. Ettayebi K, Crawford SE, Murakami K, Broughman JR, Karandikar U, Tenge VR, et al. Replication of human noroviruses in stem cell-derived human enteroids. Science (2016) 353:1387-93. doi:10.1126/science.aaf5211
42. Saxena K, Simon LM, Zeng XL, Blutt SE, Crawford SE, Sastri NP, et al. A paradox of transcriptional and functional innate interferon responses of human intestinal enteroids to enteric virus infection. Proc Natl Acad Sci U S A (2017) 114(4):E570-9. doi:10.1073/pnas.1615422114
43. Jilg N, Lin W, Hong J, Schaefer EA, Wolski D, Meixong J, et al. Kinetic differences in the induction of interferon stimulated genes by interferon-a and interleukin 28B are altered by infection with hepatitis C virus. Hepatology (2014) 59:1250-61. doi:10.1002/hep.26653
44. Bolen CR, Ding S, Robek MD, Kleinstein SH. Dynamic expression profiling of type I and type III interferon-stimulated hepatocytes reveals a stable hierarchy of gene expression. Hepatology (2014) 59:1262-72. doi:10.1002/hep.26657
45. Olagnier D, Hiscott J. Type I and type III interferon-induced immune response: it's a matter of kinetics and magnitude. Hepatology (2014) 59:1225-8. doi:10.1002/hep.26959
46. Wack A, Terczynska-Dyla E, Hartmann R. Guarding the frontiers: the biology of type III interferons. Nat Immunol (2015) 16:802-9. doi:10.1038/ni.3212
47. Arnold MM, Sen A, Greenberg HB, Patton JT. The battle between rotavirus and its host for control of the interferon signaling pathway. PLoS Pathog (2013) 9:e1003064. doi:10.1371/journal.ppat.1003064
48. Nice TJ, Baldridge MT, McCune BT, Norman JM, Lazear HM, Artyomov M, et al. Interferon-γ cures persistent murine norovirus infection in the absence of adaptive immunity. Science (2015) 347:269-73. doi:10.1126/science.1258100
49. Stanifer ML, Rippert A, Kazakov A, Willemsen J, Bucher D, Bender S, et al. Reovirus intermediate subviral particles constitute a strategy to infect intestinal epithelial cells by exploiting TGF-β dependent pro-survival signaling. Cell Microbiol (2016) 18(12):1831-45. doi:10.1111/cmi.12626
50. Cureton DK, Massol RH, Saffarian S, Kirchhausen TL, Whelan SPJ. Vesicular stomatitis virus enters cells through vesicles incompletely coated with clathrin that depend upon actin for internalization. PLoS Pathog (2009) 5:e1000394. doi:10.1371/journal.ppat.1000394
51. Stanifer ML, Cureton DK, Whelan SPJ. A recombinant vesicular stomatitis virus bearing a lethal mutation in the glycoprotein gene uncovers a second site suppressor that restores fusion. J Virol (2011) 85:8105-15. doi:10.1128/JVI.00735-11
52. Sato T, Vries RG, Snippert HJ, van de Wetering M, Barker N, Stange DE, et al. Single Lgr5 stem cells build crypt-villus structures in vitro without a mesenchymal niche. Nature (2009) 459:262-5. doi:10.1038/nature07935
53. Sato T, Stange DE, Ferrante M, Vries RG, Van Es JH, Van den Brink S, et al. Long-term expansion of epithelial organoids from human colon, adenoma, adenocarcinoma, and Barrett's epithelium. Gastroenterology (2011) 141:1762-72. doi:10.1053/j.gastro.2011.07.050
54. Date S, Sato T. Mini-gut organoids: reconstitution of the stem cell niche. Annu Rev Cell Dev Biol (2015) 31:269-89. doi:10.1146/annurev-cellbio-100814-125218
55. Hillyer P, Mane VP, Schramm LM, Puig M, Verthelyi D, Chen A, et al. Expression profiles of human interferon-alpha and interferon-lambda subtypes are ligand-and cell-dependent. Immunol Cell Biol (2012) 90:774-83. doi:10.1038/icb.2011.109